BCHE and Alzheimer disease: Up to now, AD is mainly treated by focusing on decelerating cognition decline using clinically approved medications, such as cholinesterase inhibitors, including donepezil, rivastigmine, and galantamine, for mild and moderate AD (Birks, 2006), and memantine, a medication antagonizing the N-methyl-D-aspartate receptor, for moderate and severe AD (McShane et al., 2019).